Cargando…
Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study
BACKGROUND: Rash eruptions are a common side-effect of pemetrexed, for which the administration of 8 mg/day of dexamethasone for 3 days from the day preceding pemetrexed administration is recommended. This study aimed to prospectively assess the effectiveness of prophylactic administration of low-do...
Autores principales: | Sakurada, Takumi, Nokihara, Hiroshi, Koga, Tadashi, Zamami, Yoshito, Goda, Mitsuhiro, Yagi, Kenta, Hamano, Hirofumi, Aizawa, Fuka, Ogino, Hirokazu, Sato, Seidai, Kirino, Yasushi, Goto, Hisatsugu, Nishioka, Yasuhiko, Ishizawa, Keisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255977/ https://www.ncbi.nlm.nih.gov/pubmed/35325241 http://dx.doi.org/10.1093/oncolo/oyab077 |
Ejemplares similares
-
Drug-Repositioning Approaches Based on Medical and Life Science Databases
por: Zamami, Yoshito, et al.
Publicado: (2021) -
Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
por: Okada, Naoto, et al.
Publicado: (2020) -
Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage
por: Yoshioka, Toshihiko, et al.
Publicado: (2023) -
Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
por: Kanda, Masaya, et al.
Publicado: (2022) -
A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
por: Yabuki, Yohei, et al.
Publicado: (2023)